Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals announced that on August 1, 2026, it granted inducement awards to five new employees. These awards include options to purchase up to 59,250 shares of common stock under the Company's 2023 Inducement Plan. The stock options will vest over four years, with a 25% initial vesting on the one-year anniversary, followed by monthly vesting over the subsequent 36 months, contingent on continued employment.

Syndax Pharmaceuticals reported a significant increase in total revenues for Q2 2026, rising 91.8% to $72.8 million, driven by strong product and collaboration revenue growth. The company also narrowed its net loss to $49.4 million, an improvement from $71.8 million in the prior year. Cash and cash equivalents substantially increased to $336.5 million, partly due to proceeds from a $250 million convertible note issuance.

Syndax Pharmaceuticals reported strong second-quarter 2026 financial results, with total revenue increasing 92% year-over-year to $72.8 million. This growth was driven by a 91% increase in Revuforj net revenue to $54.7 million and a 93% rise in Niktimvo collaboration revenue to $18.1 million. The company also expanded its pipeline with two new assets, SNDX-4321 and SNDX-62122, and anticipates key Phase 2 data readouts for axatilimab in IPF and frontline cGVHD in Q4 2026. Syndax expects to reach profitability with its current cash and anticipated revenues.

Syndax Pharmaceuticals reported strong financial results for the second quarter of 2026, with total revenue increasing 92% year-over-year to $72.8 million. This growth was driven by significant increases in net revenue for both Revuforj ($54.7 million, up 91%) and Niktimvo ($60.3 million, up 67%), with Niktimvo contributing $18.1 million in collaboration revenue. The company also provided positive updates on its expanded pipeline, including two new assets and anticipated topline data from key Phase 2 trials in Q4 2026, and expects to reach profitability with its current financial position and projected revenues.

Syndax Pharmaceuticals announced it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. Following the earnings release, the company's management will host a conference call and live audio webcast at 4:30 p.m. ET. Details for accessing the webcast and conference call, including dial-in numbers and a conference ID, were provided.

Syndax Pharmaceuticals announced its R&D strategy and new pipeline assets during an R&D Event held on July 14, 2026. The company is expanding its pipeline with SNDX-4321, a novel EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis (MF). Both new candidates are expected to have IND submissions by the end of 2026 or in 2027, with Phase 1 trials commencing in 2027. Additionally, the Phase 2 trial of axatilimab in IPF remains on track for topline data in Q4 2026.

Syndax Pharmaceuticals announced it granted inducement awards to eight new employees on July 1, 2026. These awards allow the purchase of up to 250,700 shares of common stock under the company's 2023 Inducement Plan. The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over the subsequent 36 months, contingent on continued employment.

Syndax Pharmaceuticals highlighted robust Revuforj (revumenib) data at the EHA 2026 Congress, showcasing strong activity across multiple acute leukemia subtypes and settings. Key findings included an 82% overall response rate in a real-world study, a 97% composite complete remission rate in a Phase 1 trial for newly diagnosed AML, and an 88% overall response rate in the Phase 2 SAVE trial for relapsed/refractory AML. These results underscore the potential for revumenib, an FDA-approved menin inhibitor, to significantly improve patient outcomes.

Syndax Pharmaceuticals' stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP) at the Annual Meeting on June 10, 2026. The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock, along with shares recycled from the previous 2015 plan, to incentivize employees, directors, and consultants. The 2026 ESPP, a successor to the 2015 ESPP, aims to secure and retain employees by allowing them to purchase company common stock. Additionally, stockholders elected directors, approved executive compensation on an advisory basis, and ratified the selection of the independent auditor.

Syndax Pharmaceuticals announced it granted inducement awards to four new employees on June 1, 2026. These awards allow the purchase of up to 66,700 shares of common stock under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over the subsequent 36 months, subject to continued employment.